CPC C07K 16/2827 (2013.01) [A61P 35/00 (2018.01); C07K 16/44 (2013.01); A61K 2039/507 (2013.01); C07K 2317/33 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] | 13 Claims |
1. A method of reducing or slowing growth of a PD-L1-positive tumor in a subject in need thereof, comprising administering to a subject having a PD-L1 positive tumor a combination of effective amounts of a first and a second isolated antibody, wherein said first antibody selectively binds to glycosylated PD-L1; and wherein said second antibody selectively binds to glycosylated PD-L1,
wherein the first isolated antibody has a VH domain comprising a CDR H1 with an amino acid sequence of SEQ ID NO: 4, a CDR H2 with an amino acid sequence of SEQ ID NO: 6, and a CDR H3 with an amino acid sequence of SEQ ID NO:8, or a VH domain comprising a CDR H1 with an amino acid sequence of SEQ ID NO: 5, a CDR H2 with an amino acid sequence of SEQ ID NO: 7, and a CDR H3 with an amino acid sequence of SEQ ID NO: 9 and a VL domain comprising a CDR L1 with an amino acid sequence of SEQ ID NO: 12, a CDR L2 with an amino acid sequence of SEQ ID NO: 14, and a CDR L3 with an amino acid sequence of SEQ ID NO: 16 and
wherein the second isolated antibody has a VH domain comprising a CDR H1 with an amino acid sequence of SEQ ID NO: 45, a CDR H2 with an amino acid sequence of SEQ ID NO: 47, and a CDR H3 with an amino acid sequence of SEQ ID NO: 49, or a VH domain comprising a CDR H1 with an amino acid sequence of SEQ ID NO: 46, a CDR H2 with an amino acid sequence of SEQ ID NO: 48, and a CDR H3 with an amino acid sequence of SEQ ID NO: 50 and a VL domain comprising a CDR L1 with an amino acid sequence of SEQ ID NO: 53, a CDR L2 with an amino acid sequence of SEQ ID NO: 55, and a CDR L3 with an amino acid sequence of SEQ ID NO: 57 or
wherein the second isolated antibody has a VH domain comprising a CDR H1 with an amino acid sequence of SEQ ID NO: 61, a CDR H2 with an amino acid sequence of SEQ ID NO: 63, and a CDR H3 with an amino acid sequence of SEQ ID NO: 65 or a VH comprising a CDR H1 with an amino acid sequence of SEQ ID NO: 62, a CDR H2 with an amino acid sequence of SEQ ID NO: 64, and a CDR H3 with an amino acid sequence of SEQ ID NO: 66 and a VL domain comprising a CDR L1 with an amino acid sequence of SEQ ID NO: 69, a CDR L2 with an amino acid sequence of SEQ ID NO: 71, and a CDR L3 with an amino acid sequence of SEQ ID NO: 73.
|